Project Grant R21CA317745
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $396K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Augusta, GA 30912, USA
Similar Awards
- The National Cancer Institute awarded the University of Southern California $699,303 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify pre-diagnostic epigenetic biomarkers of colorectal cancer risk and understand epigenetic mechanisms of lifestyle and genetic CRC risk factors across multiple U.S. populations. The research will conduct a nested case-control study of 1,500 colorectal cancer cases and 1,500 matched controls drawn from the...
- The National Cancer Institute awarded Augusta University Research Institute, Inc. $568,713 on September 2, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the critical role of heat shock factor 2 (HSF2) and heat shock protein 110 (HSP110) in regulating pre-mRNA splicing and radiation response in pancreatic ductal adenocarcinoma (PDAC). The award funds research examining how HSF2 and HSP110 upregulation in response to X-irradiation affects transcriptional...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $704,182 under the Cancer Biology Research program (CFDA 93.396) on June 16, 2026, to dissect non-mutational mechanisms driving benign-to-malignant transition in colorectal cancer. The project uses a novel mouse model that stepwise acquires mutations mirroring human colorectal cancer progression—starting with APC knockout to initiate benign polyps, then inducing KRAS G12V and TP53 loss in rare cells within established polyps...
- The National Cancer Institute awarded Emory University $682,730 on August 13, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a patient-centered value assessment informing value-based insurance design models for outpatient specialty palliative care in advanced cancer. The project, titled UNCOVER-PC: Uniting Novel Concepts of Value to Enhance Reform in Palliative Care, addresses low uptake of specialty palliative care among advanced cancer patients—only 10...
- The National Cancer Institute awarded The University of Chicago $692,063 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance early colorectal cancer diagnosis and risk stratification using DNA methylation markers. The funded work develops blood-based biomarkers to detect colorectal cancer and advanced adenomas through cell-free DNA analysis, addressing the gap in sensitivity of existing tools such as MSEPT9, Cologuard, and Shield. The research...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $4.17 million Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded September 10, 2025, with completion targeted for August 31, 2029. The award supports a comprehensive genetic and translational research initiative titled "Leveraging Omics and Electronic Health Records Data to Study Colorectal Adenoma Genetics and Drug Repurposing."...
- The National Cancer Institute awarded Ochin, Inc. $1.267 million on September 23, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a longitudinal, multi-level study examining the associations between social risk screening, social risk factors, and cancer healthcare utilization and outcomes among Latino and community health center patients. The study uses electronic health record data from a community health center network operating across more than 40 states,...
- The National Cancer Institute awarded the University of Pittsburgh $649,620 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to examine Medicare Advantage plan impacts on cancer care access, quality, and outcomes for older adults. The project investigates whether Medicare Advantage's limited provider networks create barriers to timely specialty care for patients with the four most prevalent cancers—breast, colorectal, lung, and prostate. The research employs...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $727,971 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize the tumor-associated microbiome in early-onset rectal cancers and elucidate the microenvironment of this emerging disease. The award funds a five-year research project (August 1, 2026 through July 31, 2031) examining distinctive microbial features—both bacterial and fungal—in early-onset cancers of the sigmoid colon...
- Federal Grant Award Summary The National Cancer Institute awarded a $248,998 Project Grant to Massachusetts General Hospital on September 16, 2025, under the Cancer Treatment Research program (CFDA 93.395) to support research titled "Integrating a Multi-Omics Cohort Study with a Medically Tailored Meal Intervention to Target Ultra-Processed Foods for Colorectal Cancer Prevention and Control." The award, which extends through August 31, 2028, funds a two-phase research initiative...